Clinical Trial Update: Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating efficacy and safety of SG001 in combination with PLD for platinum-resistant relapsed epithelial ovarian cancer, fallopian tube…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• PLD (pegylated liposomal doxorubicin)
• SG001

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: UNKNOWN